These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

256 related items for PubMed ID: 7958476

  • 1. Mucosal vaccines based on the use of cholera toxin B subunit as immunogen and antigen carrier.
    Lebens M, Holmgren J.
    Dev Biol Stand; 1994; 82():215-27. PubMed ID: 7958476
    [Abstract] [Full Text] [Related]

  • 2. Strategies for the induction of immune responses at mucosal surfaces making use of cholera toxin B subunit as immunogen, carrier, and adjuvant.
    Holmgren J, Czerkinsky C, Lycke N, Svennerholm AM.
    Am J Trop Med Hyg; 1994; 50(5 Suppl):42-54. PubMed ID: 8203723
    [Abstract] [Full Text] [Related]

  • 3. Development and preclinical evaluation of safety and immunogenicity of an oral ETEC vaccine containing inactivated E. coli bacteria overexpressing colonization factors CFA/I, CS3, CS5 and CS6 combined with a hybrid LT/CT B subunit antigen, administered alone and together with dmLT adjuvant.
    Holmgren J, Bourgeois L, Carlin N, Clements J, Gustafsson B, Lundgren A, Nygren E, Tobias J, Walker R, Svennerholm AM.
    Vaccine; 2013 May 07; 31(20):2457-64. PubMed ID: 23541621
    [Abstract] [Full Text] [Related]

  • 4. Cholera toxin and cholera B subunit as oral-mucosal adjuvant and antigen vector systems.
    Holmgren J, Lycke N, Czerkinsky C.
    Vaccine; 1993 Sep 07; 11(12):1179-84. PubMed ID: 8256498
    [Abstract] [Full Text] [Related]

  • 5. Mucosal and systemic antibody responses after peroral or intranasal immunization: effects of conjugation to enterotoxin B subunits and/or of co-administration with free toxin as adjuvant.
    Rask C, Fredriksson M, Lindblad M, Czerkinsky C, Holmgren J.
    APMIS; 2000 Mar 07; 108(3):178-86. PubMed ID: 10752686
    [Abstract] [Full Text] [Related]

  • 6. Expression of the cholera toxin B subunit (CT-B) in maize seeds and a combined mucosal treatment against cholera and traveler's diarrhea.
    Karaman S, Cunnick J, Wang K.
    Plant Cell Rep; 2012 Mar 07; 31(3):527-37. PubMed ID: 21938449
    [Abstract] [Full Text] [Related]

  • 7. Synergistic action of cholera toxin B subunit (and Escherichia coli heat-labile toxin B subunit) and a trace amount of cholera whole toxin as an adjuvant for nasal influenza vaccine.
    Tamura S, Yamanaka A, Shimohara M, Tomita T, Komase K, Tsuda Y, Suzuki Y, Nagamine T, Kawahara K, Danbara H.
    Vaccine; 1994 Apr 07; 12(5):419-26. PubMed ID: 8023550
    [Abstract] [Full Text] [Related]

  • 8. Sublingual Adjuvant Delivery by a Live Attenuated Vibrio cholerae-Based Antigen Presentation Platform.
    Liao J, Gibson JA, Pickering BS, Watnick PI.
    mSphere; 2018 Jun 27; 3(3):. PubMed ID: 29875145
    [Abstract] [Full Text] [Related]

  • 9. Antibody-secreting cells in human peripheral blood after oral immunization with an inactivated enterotoxigenic Escherichia coli vaccine.
    Wennerås C, Svennerholm AM, Ahrén C, Czerkinsky C.
    Infect Immun; 1992 Jul 27; 60(7):2605-11. PubMed ID: 1612730
    [Abstract] [Full Text] [Related]

  • 10. [Cholera immunology and the molecular biology of cholera toxin. Recent progress and future prospects].
    Carrada Bravo T.
    Rev Alerg; 1993 Jul 27; 40(4):91-4. PubMed ID: 8143024
    [Abstract] [Full Text] [Related]

  • 11. Secretory IgA-mediated protection against V. cholerae and heat-labile enterotoxin-producing enterotoxigenic Escherichia coli by rice-based vaccine.
    Tokuhara D, Yuki Y, Nochi T, Kodama T, Mejima M, Kurokawa S, Takahashi Y, Nanno M, Nakanishi U, Takaiwa F, Honda T, Kiyono H.
    Proc Natl Acad Sci U S A; 2010 May 11; 107(19):8794-9. PubMed ID: 20421480
    [Abstract] [Full Text] [Related]

  • 12. Induction of mucosal immunity by intranasal application of a streptococcal surface protein antigen with the cholera toxin B subunit.
    Wu HY, Russell MW.
    Infect Immun; 1993 Jan 11; 61(1):314-22. PubMed ID: 8418053
    [Abstract] [Full Text] [Related]

  • 13. Mucosal adjuvants and anti-infection and anti-immunopathology vaccines based on cholera toxin, cholera toxin B subunit and CpG DNA.
    Holmgren J, Adamsson J, Anjuère F, Clemens J, Czerkinsky C, Eriksson K, Flach CF, George-Chandy A, Harandi AM, Lebens M, Lehner T, Lindblad M, Nygren E, Raghavan S, Sanchez J, Stanford M, Sun JB, Svennerholm AM, Tengvall S.
    Immunol Lett; 2005 Mar 15; 97(2):181-8. PubMed ID: 15752556
    [Abstract] [Full Text] [Related]

  • 14. Clinical trial to evaluate safety and immunogenicity of an oral inactivated enterotoxigenic Escherichia coli prototype vaccine containing CFA/I overexpressing bacteria and recombinantly produced LTB/CTB hybrid protein.
    Lundgren A, Leach S, Tobias J, Carlin N, Gustafsson B, Jertborn M, Bourgeois L, Walker R, Holmgren J, Svennerholm AM.
    Vaccine; 2013 Feb 06; 31(8):1163-70. PubMed ID: 23306362
    [Abstract] [Full Text] [Related]

  • 15. Intestinal antibody response after oral immunization with a prototype cholera B subunit-colonization factor antigen enterotoxigenic Escherichia coli vaccine.
    Ahrén C, Wennerås C, Holmgren J, Svennerholm AM.
    Vaccine; 1993 Feb 06; 11(9):929-34. PubMed ID: 8212839
    [Abstract] [Full Text] [Related]

  • 16. Cholera toxin B subunit modulation of mucosal vaccines for infectious and autoimmune diseases.
    Langridge W, Dénes B, Fodor I.
    Curr Opin Investig Drugs; 2010 Aug 06; 11(8):919-28. PubMed ID: 20721834
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Robust gut associated vaccine-specific antibody-secreting cell responses are detected at the mucosal surface of Bangladeshi subjects after immunization with an oral killed bivalent V. cholerae O1/O139 whole cell cholera vaccine: comparison with other mucosal and systemic responses.
    Shamsuzzaman S, Ahmed T, Mannoor K, Begum YA, Bardhan PK, Sack RB, Sack DA, Svennerholm AM, Holmgren J, Qadri F.
    Vaccine; 2009 Feb 25; 27(9):1386-92. PubMed ID: 19146897
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.